Acadesine

Acadesine

SCHEMBL219336

NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PRKAA1PRKAA2PRKAB1PRKAB2PRKAG1PRKAG2PRKAG3

The experimentally established mechanism targets of Acadesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 1.00
TP53 P04637 2/20 1.00
TDP1 Q9NUW8 1/20 1.00
MAPT P10636 1/20 1.00
SMN1; SMN2 Q16637 4/20 0.77
ALDH1A1 P00352 3/20 0.77
HTT P42858 2/20 0.77
BLM P54132 2/20 0.77
TSHR P16473 2/20 0.77
GAA P10253 1/20 0.77
FBP1 P09467 1/20 0.69
ATIC P31939 1/20 0.69
LMNA P02545 5/20 0.60
THPO P40225 2/20 0.60
PMP22 Q01453 2/20 0.60
GMNN O75496 1/20 0.60
NFKB1 P19838 1/20 0.60
DNMT1 P26358 1/20 0.60
MTOR P42345 1/20 0.60
RAB9A P51151 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acadesine SCHEMBL7141001 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL28745421 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL2619704 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL2394079 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL10017743 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL6113798 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL5053863 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL14520658 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL2631614 1.00 KDM4E (1.00) KDM4ETP53TDP1MAPTSMN1; SMN2
Acadesine SCHEMBL8722270 0.95 KDM4E (0.91) KDM4ETP53TDP1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3477 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144879-A1 ANTI-VIRAL AND HEPATIC-TARGETED DRUGS AI-BIOPHARMA (FR) 2026-05-28 US claimed
EP-4747627-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS Matterworks Inc (US) 2026-05-27 EP claimed
US-12625139-B2 Methods for modulation of acetyltransferase activity and applications thereof including treatments THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2026-05-12 US claimed
US-20260097105-A1 SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS CHILDRENS HOSPITAL PHILADELPHIA (US) 2026-04-09 US claimed
WO-2026042726-A1 EMBRYO ACQUISITION METHOD 学校法人金沢医科大学 2026-02-26 WO claimed
US-20260041336-A1 PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK NEW YORK UNIVERSITY (US) 2026-02-12 US claimed
US-20260034158-A1 METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM COMPRISING 5-ETHYNYL-2'-DEOXYURIDINE UNIV NORTH CAROLINA CHAPEL HILL (US) 2026-02-05 US claimed
EP-4652841-A1 SUBSTANCE (HATCHING ACCELERATOR) ACCELERATING HATCHING OF CYST NEMATODES Hirotsu Bio Science Inc. (JP) 2025-11-26 EP claimed
US-20250345296-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF MITOPHAGY FOR USE IN TREATMENT OF MITOCHONDRIAL DISEASE THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2025-11-13 US claimed
US-20250325501-A1 A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA UNIV OTTO VON GUERICKE MAGDEBURG (DE) 2025-10-23 US claimed
EP-0427799-B1 METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE GENSIA PHARMA (US) 1994-11-30 EP claimed
WO-1994013324-A1 LIPID PRODRUGS FOR ORAL ADMINISTRATION VESTAR, INC. (US) 1994-06-23 WO claimed
US-5030623-A Administering a purine nucleoside compound or analog; antiallergenic THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1991-07-09 US claimed
US-4912092-A Prevent tissue damage; administering purine nucleoside THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1990-03-27 US claimed
EP-0262125-A4 AICA riboside for the prophylactic treatment of diseases with restricted blood flow. GRUBER HARRY EDWARD 1989-07-26 EP claimed
EP-0262125-A1 AICA riboside for the prophylactic treatment of diseases with restricted blood flow. GRUBER HARRY EDWARD 1988-04-06 EP claimed
WO-1987005807-A1 A METHOD OF INCREASING ADENOSINE EXCRETION GRUBER HARRY EDWARD 1987-10-08 WO claimed
US-4293690-A PROTECTING HYDROXYLS OF 5-AMINO-1-B-D-RIBOFURANOSYLIMIDAZOLE-4-CARBOXAMIDE, DEHYDRATION, CYCLIZATION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1981-10-06 US claimed
US-4255565-A REACTION OF 5-AMINO-1-B-D-RIBOFURANOSYL-4-CYANOIMIDAZOLE AND AN N-CARBO-SUBSTITUTED CYANAMIDE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1981-03-10 US claimed
EP-0017465-A1 Production of 2,6-diaminonebularines Takeda Chemical Industries, Ltd. (JP) 1980-10-15 EP claimed